Akums Drugs and Pharmaceuticals Limited IPO
About the Company:
Founded in 2004, Akums Drugs and Pharmaceuticals Limited is a prominent pharmaceutical contract development and manufacturing organization (CDMO) serving both Indian and international markets.
Key Services:
Comprehensive solutions for product development and manufacturing
Formulation research and development (R&D)
Regulatory dossier preparation and submission for Indian and global markets
Testing services
Manufacturing and sale of branded drugs and active pharmaceutical ingredients (APIs)
Manufacturing Capabilities:
10 manufacturing units with a combined production capacity of 49.21 billion units annually (as of September 30, 2023)
Production of various dosage forms including tablets, capsules, liquid medicines, and more
4,025 commercialized formulations across over 60 dosage forms
Regulatory Accreditations:
European Good Manufacturing Practice (EU-GMP)
World Health Organization Good Manufacturing Practice (WHO-GMP)
United States National Sanitation Foundation (US NSF)
Objectives of the Issue: The company intends to use the net proceeds from the IPO for:
Repayment/prepayment of company and subsidiary indebtedness
Funding incremental working capital requirements
Pursuing inorganic growth initiatives through acquisitions
General corporate purposes
Akums Drugs & Pharmaceuticals IPO IPO Dates: 30 July to 1 August, 2024
Price Band : ₹646 to ₹679 per share
Lot Size: 22 shares
Total Issue size: ₹1856.74 Crores
Retail Quota: 10% GMP: 15% only for information
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.